Benitec Biopharma Ltd (BNTC)

[Wildbilly]

Benitec Lung Cancer Update - Shaw Says Buy

From Carl Stubbings:

"I’m pleased to show you the latest report from Shaw Stockbroking, one of Australia's largest independently owned full service broking firms. It reports how Benitec’s collaborator, the University of NSW (UNSW), has:

Determined the mechanism of action of beta III tubulin in drug resistant lung cancer

Validated the use of ddRNAi in silencing the beta III tubulin gene to overcome chemotherapy resistance.

In addition, the Shaw report:

Quotes the global drug market for NSCLC (non small cell lung cancer, the target of UNSW’s program) to be USD 6.9B by 2019

Comments that Benitec’s capitalisation of AUD 89M is ‘undemanding’ compared to similar US companies
Recommends ‘BUY’."

Read the full report: https://apj3.smixexpress.com/express/clients/benitec/papers/BLT_Shaw_BT_Dec_11.pdf


.